Johnston Sarah L
Department of Immunology and Immunogenetics, Southmead Hospital, Bristol, UK.
J Clin Pathol. 2007 Jan;60(1):8-17. doi: 10.1136/jcp.2005.032300.
Over the past two decades, major advances have been made in the understanding of the immune system and disease pathogenesis. This has coincided with the development of biologic therapies--monoclonal antibodies and fusion proteins. The decision of when to use such treatment in the clinic is not always straightforward. In addition to immune biology, the focus of this review will be on the application of these treatments to immune-mediated diseases and the molecular targets involved in pathogenesis, specifically those that have US Food and Drug Administration/European Medicines Agency approval. Brief comments will be made on biologics that have approval for non-immune disorders.
在过去二十年里，我们对免疫系统和疾病发病机制的理解取得了重大进展。这与生物疗法（单克隆抗体和融合蛋白）的发展同步。在临床中何时使用此类治疗的决策并非总是一目了然。除了免疫生物学，本综述的重点将是这些治疗方法在免疫介导疾病中的应用以及发病机制中涉及的分子靶点，特别是那些已获得美国食品药品监督管理局/欧洲药品管理局批准的靶点。对于已获批用于非免疫性疾病的生物制剂也将作简要评论。
